Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Assets: 2019-2025

Historic Non-Current Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $158.9 million.

  • BridgeBio Pharma's Non-Current Assets fell 27.92% to $158.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.9 million, marking a year-over-year decrease of 27.92%. This contributed to the annual value of $198.6 million for FY2024, which is 188.78% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Non-Current Assets stood at $158.9 million, which was down 5.39% from $167.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Non-Current Assets registered a high of $220.4 million during Q3 2024, and its lowest value of $65.9 million during Q1 2024.
  • For the 3-year period, BridgeBio Pharma's Non-Current Assets averaged around $132.4 million, with its median value being $158.9 million (2025).
  • As far as peak fluctuations go, BridgeBio Pharma's Non-Current Assets soared by 296.41% in 2021, and later crashed by 47.00% in 2022.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Non-Current Assets stood at $123.9 million in 2021, then plummeted by 40.14% to $74.2 million in 2022, then fell by 7.27% to $68.8 million in 2023, then spiked by 188.78% to $198.6 million in 2024, then dropped by 27.92% to $158.9 million in 2025.
  • Its Non-Current Assets was $158.9 million in Q3 2025, compared to $167.9 million in Q2 2025 and $186.5 million in Q1 2025.